Prof. Monilola Olayioye and Prof. Roland Kontermann received funding from the initiative "2+2 Verbundprojekte im Rahmen der Wissenschaftlich-Technologischen Zusammenarbeit" between Germany and Mexico supported by BMBF and Conacyt. Together with project partners from Germany (Yumab) and Mexico (RD Biotec in collaboration with UNIPREC, CIATEJ) we will develop novel bispecific antbodies for cancer therapy targeting the receptor tyrosine kinases ErbB4 and EGFR.